What is Gala?
Gala is a telehealth platform focused specifically on tirzepatide — the dual GIP/GLP-1 receptor agonist that outperformed semaglutide in the SURMOUNT trial with an average 22.5% body weight reduction at 15mg. Gala's differentiator is its microdose entry point: tirzepatide starting at $149/month ($1,788/year), which is significantly below what most competitors charge for this compound.
The tirzepatide microdose protocol is designed for patients who want to begin at a lower dose to manage side effects during the adjustment period, or for those who respond well to lower doses and don't require aggressive titration. A standard dose is available at $179/month for patients who need a higher maintenance dose.
Lab requirements vary by state — some states require baseline bloodwork before tirzepatide is prescribed; others allow more flexible intake. Gala's narrow focus means it excels for tirzepatide specifically but isn't the right choice if you need other compounds alongside GLP-1.
Treatments Offered by Gala
Tirzepatide — Microdose & Standard
Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, which produces greater weight loss than GLP-1 agonism alone. The SURMOUNT-1 trial demonstrated 22.5% average body weight reduction over 72 weeks at the 15mg dose. Gala offers this at two price tiers: microdose from $149/mo and standard from $179/mo — both physician-prescribed via licensed compounding pharmacies.
Tirzepatide microdosing (typically 1–2.5mg/week) is useful for patients who are new to GLP-1 therapy, sensitive to nausea or GI effects, or who prefer a slower titration. The lower dose can also reduce monthly cost for patients who achieve their goals without needing full titration.
Gala Pricing
Gala Protocol Pricing (2026)
How Gala Works
After completing an online intake form, a licensed physician reviews your health history and recommends a tirzepatide protocol — microdose or standard, depending on your goals and any prior GLP-1 experience. Lab requirements depend on your state. Prescriptions are issued and filled through licensed compounding pharmacies and shipped to your door.
Who Gala is Best For
- Patients specifically looking for tirzepatide at the lowest available supervised price point ($149/mo microdose is genuinely competitive)
- New-to-GLP-1 patients who want to start at a microdose to gauge tolerability before titrating
- Cost-conscious patients comparing tirzepatide options who don't need other compounds bundled in
- Anyone in a state where Gala's labs-optional intake applies, minimizing upfront friction
Who Should Look Elsewhere
- Patients who also want semaglutide — Gala focuses on tirzepatide only; try Tonik, Shed, or Maximus for both GLP-1 compounds
- Users who need NAD+, testosterone, or other compounds alongside GLP-1 — Tonik covers these at competitive pricing
- Anyone who wants the most proven, well-reviewed platform — Gala is newer with limited independent review history
- Patients needing aggressive titration support with a high dose ceiling — confirm Gala's protocol range before enrolling
Pros
- $149/mo tirzepatide microdose — one of the lowest supervised entry prices
- $1,788/year annual cost is significantly below most competitors
- Dedicated tirzepatide focus means protocol depth for this specific compound
- State-dependent labs — some patients can start without upfront bloodwork
- Physician-prescribed via licensed compounding pharmacies
Cons
- Tirzepatide only — no semaglutide, NAD+, testosterone, or other compounds
- Newer platform with limited independent review history
- No confirmed lab bundling or coaching support
- Narrower use case — won't work for multi-compound protocols
Gala vs Competitors for Tirzepatide
vs Tonik ($229/mo): Gala is $80/month cheaper for tirzepatide. Tonik adds testosterone, NAD+, and GHK-Cu. Choose Gala if you only need tirzepatide; choose Tonik if you want additional compounds.
vs Shed ($299/mo): Gala is $150/month cheaper for tirzepatide. Shed adds semaglutide, NAD+, and non-injectable GLP-1 options. For tirzepatide-only, Gala is the better value.
vs MadeMed ($149/mo sema, $189/mo tirz): Gala's $149/mo microdose tirzepatide undercuts MadeMed's tirzepatide pricing. MadeMed requires a $149/yr membership for best rates and offers a broader formulary. Gala wins on tirzepatide price; MadeMed wins on breadth.
See: Full tirzepatide provider comparison →
Our Verdict on Gala
Gala's value proposition is simple and compelling: it offers tirzepatide at one of the lowest supervised prices available — $149/month for microdose, $179/month standard. For patients who have decided on tirzepatide and want physician supervision without paying a premium, Gala delivers that cleanly.
The limitation is equally clear: Gala does one thing. If you want semaglutide, NAD+, testosterone, or any other compound alongside your GLP-1 therapy, you'll need a different or additional platform. But as a focused tirzepatide entry point, Gala represents genuine value.
Rating: 7.3/10 — Best for Lowest-Cost Supervised Tirzepatide